Ultragenyx Pharmaceutical Inc.
US ˙ NasdaqGS ˙ US90400D1081

SecurityRARE / Ultragenyx Pharmaceutical Inc.
InstitutionFranklin Resources Inc
Latest Disclosed Ownership312,628 shares
Latest Disclosed Value $ 6,549,556
Franklin Resources Inc reports 1.15% increase in ownership of RARE / Ultragenyx Pharmaceutical Inc.

On May 13, 2026 - Franklin Resources Inc filed a 13F-HR form disclosing ownership of 312,628 shares of Ultragenyx Pharmaceutical Inc. (US:RARE) valued at $6,549,557 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 309,062 shares of Ultragenyx Pharmaceutical Inc.. This represents a change in shares of 1.15% during the quarter. The current value of the position is $7,005,993 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 312,628 3,566 1.15 6,550 -7.86 0.0016
2026-02-11 2025-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 309,062 -368,122 -54.36 7,108 -65.10 0.0017
2025-11-13 2025-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 677,184 202,028 42.52 20,370 17.90 0.0051
2025-08-12 2025-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 475,156 -125,290 -20.87 17,277 -20.54 0.0046
2025-05-13 2025-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 600,446 173,087 40.50 21,742 20.94 0.0063
2025-02-12 2024-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 427,359 208,456 95.23 17,979 46.16 0.0050
2024-11-27 2024-09-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 218,903 -74,991 -25.52 12,300 1.83 0.0035
2024-11-12 2024-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 218,903 -74,991 12,300 0.0006
2024-08-14 2024-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 293,894 77,978 36.11 12,079 19.82 0.0037
2024-05-13 2024-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 215,916 1,178 0.55 10,081 -1.82 0.0032
2024-02-09 2023-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 214,738 25,144 13.26 10,269 51.92 0.0048
2023-11-13 2023-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 189,594 9,976 5.55 6,759 -18.42 0.0034
2023-08-11 2023-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 179,618 126 0.07 8,286 15.12 0.0039
2023-05-12 2023-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 179,492 -1,600 -0.88 7,198 -14.21 0.0036
2023-02-10 2022-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 181,092 2,729 1.53 8,390 13.58 0.0044
2022-11-14 2022-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 178,363 -834 -0.47 7,386 -30.91 0.0040
2022-08-11 2022-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 179,197 0 0.00 10,691 -17.84 0.0053
2022-05-13 2022-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 179,197 -14 -0.01 13,013 -13.65 0.0052
2022-02-11 2021-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 179,211 -23,250 -11.48 15,070 -17.47 0.0054
2021-11-12 2021-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 202,461 76 0.04 18,260 -5.38 0.0069
2021-08-13 2021-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 202,385 -42 -0.02 19,298 -16.27 0.0074
2021-05-13 2021-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 202,427 -51,651 -20.33 23,048 -34.47 0.0094
2021-02-10 2020-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 254,078 -128,749 -33.63 35,172 11.78 0.0149
2020-11-12 2020-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 382,827 354 0.09 31,464 -0.83 0.0152
2020-08-13 2020-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 382,473 0 0.00 31,726 86.70 0.0163
2020-05-13 2020-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 382,473 11,823 3.19 16,993 7.35 0.0113
2020-03-11 2019-12-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 370,650 225,200 154.83 15,830 154.42 0.0083
2020-02-12 2019-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 370,650 225,200 15,830 1,999.5457
2019-11-14 2019-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 145,450 145,450 6,222 0.0034
2016-05-10 2016-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 0 0 0 0.0000
2016-04-27 2015-12-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 0 0 0 0.0000
2015-11-10 2015-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 0 -214,300 -100.00 0 -100.00
2015-08-12 2015-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 214,300 0 0.00 21,942 64.90 0.0100
2015-05-14 2015-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 214,300 0 0.00 13,306 41.51 0.0060
2015-02-10 2014-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 214,300 -6,500 -2.94 9,403 -24.76 0.0043
2014-11-12 2014-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 220,800 -22,300 -9.17 12,497 14.51 0.0057
2014-08-12 2014-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 243,100 0 0.00 10,913 -8.18 0.0048
2014-05-13 2014-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 243,100 243,100 11,885 0.0056
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.